论文部分内容阅读
目的探究不同疗程标准三联疗法治疗幽门螺杆菌感染的临床疗效。方法 240例消化性溃疡或慢性胃炎患者,随机分为甲组与乙组,各120例。甲组采用20 mg雷贝拉唑+0.5 mg克拉霉素+1 g阿莫西林,进行为期1周的治疗;乙组采用同样的给药方式,进行为期2周的疗程。对两组患者的治疗效果与不良反应情况进行观察与对比。结果两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。乙组患者的幽门螺杆菌根除率为93.33%,明显高于甲组的71.67%,差异有统计学意义(P<0.05)。结论标准的三联疗法对幽门螺杆菌感染具有一定的治疗效果,还可以作为首选的治疗方案,但必须将其疗程有所延长。
Objective To investigate the clinical efficacy of different courses of standard triple therapy in the treatment of Helicobacter pylori infection. Methods A total of 240 patients with peptic ulcer or chronic gastritis were randomly divided into group A and group B, with 120 cases in each group. Group A with 20 mg of rabeprazole +0.5 mg clarithromycin +1 g amoxicillin for a period of 1 week of treatment; Group B using the same mode of administration for a period of 2 weeks of treatment. The two groups of patients with treatment and adverse reactions were observed and compared. Results There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). The eradication rate of Helicobacter pylori in group B was 93.33%, which was significantly higher than that in group A (71.67%), the difference was statistically significant (P <0.05). Conclusion The standard triple therapy has a certain therapeutic effect on Helicobacter pylori infection, but also can be used as the first choice of treatment, but its treatment must be extended.